The FDA recently warned about 30 telehealth companies for marketing compounded GLP-1 drugs for weight loss. These medications are not FDA-approved and may be promoted in ways that could mislead patients. The situation raises concerns about patient safety and regulation as telehealth prescribing continues to grow. Read more here.